Schisanhenol(Synonyms: Schizanhenol; Gomisin-K3)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Schisanhenol (Synonyms: Schizanhenol; Gomisin-K3) 纯度: 99.70%

五味子酚(Schisanhenol)是一天然化合物,被报道是UGT2B7的抑制剂。

Schisanhenol(Synonyms: Schizanhenol;  Gomisin-K3)

Schisanhenol Chemical Structure

CAS No. : 69363-14-0

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥2420 In-stock
10 mg ¥2200 In-stock
25 mg ¥4100 In-stock
50 mg ¥6750 In-stock
100 mg ¥9400 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Schisanhenol 相关产品

相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Phenols Library
  • Traditional Chinese Medicine Monomer Library

生物活性

Schisanhenol is a natural compound solated from Schisandra rubriflora; UGT2B7 UDP-glucuronosyltransferases inhibitor. IC50 value: Target: in vitro: Schisanhenol exhibited strong inhibition toward UGT2B7, with the residual activity to be 7.9% of control activity [1]. The BAECs were cultured with ox-LDL (200 microg/ml) in the presence and absence of Sal (10 and 50 micromol L(- 1)) for 24 h. The cytotoxicity of ox-LDL was evaluated by LDH leakage, cell viability and morphological change. Cell apoptosis was estimated by DNA ladder, chromatin condensation, and flow cytometry assay. The intracellular ROS production was detected by using DCF, a ROS probe, with laser confocal microscopy and flow cytometry. Sal was shown to reduce LDH leakage and increase cell viability. Sal also attenuated ox-LDL-induced BAECs apoptosis as indicated in typical internucleosomal DNA degradation (DNA ladder), condensed chromatin, and the sub-G1 peak appearance in flow cytometry assay [2]. in vivo: Sal significantly impeded production of MDA and loss of ATPase activity induced by reoxygenation following anoxia. Oral administration of Sal induced increase of cytosol glutathione-peroxidase of brain in mice under the condition of reoxygenation following anoxia [4].

分子量

402.48

Formula

C23H30O6

CAS 号

69363-14-0

中文名称

五味子酚;去甲去氧五味子素

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 250 mg/mL (621.15 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.4846 mL 12.4230 mL 24.8460 mL
5 mM 0.4969 mL 2.4846 mL 4.9692 mL
10 mM 0.2485 mL 1.2423 mL 2.4846 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 6.25 mg/mL (15.53 mM); Clear solution

    此方案可获得 ≥ 6.25 mg/mL (15.53 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 62.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 6.25 mg/mL (15.53 mM); Clear solution

    此方案可获得 ≥ 6.25 mg/mL (15.53 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 62.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Song JH, et al. Inhibition of UDP-Glucuronosyltransferases (UGTs) Activity by constituents of Schisandra chinensis. Phytother Res. 2015 Jun 18.

    [2]. Yu LH, et al. Schisanhenol attenuated ox-LDL-induced apoptosis and reactive oxygen species generation in bovine aorta endothelial cells in vitro. J Asian Nat Prod Res. 2008 Jul-Aug;10(7-8):799-806.

    [3]. Wang QY, et al. Schisanhenol derivatives and their biological evaluation against tobacco mosaic virus (TMV). Fitoterapia. 2015 Mar;101:117-24.

    [4]. Xue JY, et al. Antioxidant activity of two dibenzocyclooctene lignans on the aged and ischemic brain in rats. Free Radic Biol Med. 1992;12(2):127-35.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务